The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Heart Valve Disease
Volume 11 - 2024 |
doi: 10.3389/fcvm.2024.1504197
The expanding role of 16s Ribosomal RNA PCR in the management of patients with infective endocarditis undergoing cardiac surgery
Provisionally accepted- 1 Department of Cardiovascular Sciences, Agostino Gemelli University Polyclinic (IRCCS), Rome, Lazio, Italy
- 2 Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
- 3 Department of Laboratory and Infectious Science, Agostino Gemelli University Polyclinic (IRCCS), Rome, Lazio, Italy
- 4 Laboratorio di Endocrinologia Cardiovascolare, San Raffaele Pisana (IRCCS), Rome, Lazio, Italy
Aetiological diagnosis and targeted antibiotic therapy are essential to improve the prognosis of patients with infective endocarditis. Molecular tests on blood have been reported to be effective in identifying the causative organism and are recommended when blood cultures are negative. The role of molecular tests on the surgically excised valve is still unclear and needs further investigation.In this prospective, observational, single center study, we enrolled 100 consecutive patients with native or prosthetic valve endocarditis who underwent cardiac surgery between April 2020 and June 2023. Results of preoperative blood cultures, valve culture, 16s ribosomal RNA and histopathologic analysis of surgical samples were collected in a dedicated database.The mean age of the study population was 60 ± 12.5 years, with a majority of men (73%). Previous cardiac surgery was reported in 31% of patients. Blood culture, valve culture, and 16srRNA were positive in 83%, 47%, and 76% of cases, respectively. The sensitivity of both valve culture and 16srRNA decreased significantly with prolonged preoperative antibiotic therapy. Of note, 16srRNA was the only positive result in 7% of cases, allowing aetiological diagnosis. In 33% of patients, the valve culture test was negative while the molecular test was positive. In these cases, histopathological analysis showed acute inflammation in most cases. In 10%, the molecular test helped in resolving discrepancies between the results of blood and valve cultures.The molecular test showed significantly higher diagnostic sensitivity than valve culture and maintained this efficacy even after 28 days of preoperative antibiotic therapy. In addition to identifying the pathogen in 7% of cases with negative culture results, the molecular test demonstrated utility in other crucial situations. When valve cultures were negative, combining molecular testing and histopathological analysis they allowed the identification of patients who could benefit from prolonged antibiotic therapy. In addition, molecular testing guided the choice of antibiotic treatment when there was a discrepancy between blood culture and valve culture results. Based on these findings, molecular testing should be considered in all patients with infective endocarditis undergoing cardiac surgery. Study protocol was registered on ClinicalTrials.gov (ID: NCT05791357).
Keywords: Infective endocarditis, Heart Valve Prosthesis, 16s ribosomal RNA PCR, cardiac surgery, Molecular test
Received: 30 Sep 2024; Accepted: 02 Dec 2024.
Copyright: © 2024 Pavone, Cammertoni, Calabrese, Bruno, Scoppettuolo, Lombardo, Giovannenze, Taddei, Fiori, D'inzeo, Cutrone, Iannaccone, Del Zanna and Massetti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Natalia Pavone, Department of Cardiovascular Sciences, Agostino Gemelli University Polyclinic (IRCCS), Rome, 00168, Lazio, Italy
Federico Cammertoni, Department of Cardiovascular Sciences, Agostino Gemelli University Polyclinic (IRCCS), Rome, 00168, Lazio, Italy
Piergiorgio Bruno, Department of Cardiovascular Sciences, Agostino Gemelli University Polyclinic (IRCCS), Rome, 00168, Lazio, Italy
Giancarlo Scoppettuolo, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
Antonella Lombardo, Department of Cardiovascular Sciences, Agostino Gemelli University Polyclinic (IRCCS), Rome, 00168, Lazio, Italy
Francesca Giovannenze, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
Eleonora Taddei, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy
Barbara Fiori, Department of Laboratory and Infectious Science, Agostino Gemelli University Polyclinic (IRCCS), Rome, 00168, Lazio, Italy
Tiziana D'inzeo, Department of Laboratory and Infectious Science, Agostino Gemelli University Polyclinic (IRCCS), Rome, 00168, Lazio, Italy
Giulia Iannaccone, Department of Cardiovascular Sciences, Agostino Gemelli University Polyclinic (IRCCS), Rome, 00168, Lazio, Italy
Niccolo Del Zanna, Laboratorio di Endocrinologia Cardiovascolare, San Raffaele Pisana (IRCCS), Rome, Lazio, Italy
Massimo Massetti, Department of Cardiovascular Sciences, Agostino Gemelli University Polyclinic (IRCCS), Rome, 00168, Lazio, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.